Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,780
Completed, industry sponsors, Infectious disease and vaccines, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,780
1,780 trials
Showing 1 to 25, recently updated first.
Memorises BioIndustry
NCT05351437 · 32 participants · Start Apr 26, 2022 · Primary completion Sep 4, 2022
Drug: MTx-COVAB36; Placebo · For: SARS-CoV-2 Infection
Sites: Nedlands, Australia
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult ParticipantsPivotal-lookingCompleted
Sinovac Life Sciences Co., Ltd.Industry
NCT06939777 · 255 participants · Start Apr 28, 2025 · Primary completion Dec 8, 2025
Drug: SNA02-48; Placebo and 2 more · For: Tetanus
Sites: Hefei, China
ViiV HealthcareGSK (GSK)
NCT04757974 · 48 participants · Start Mar 5, 2021 · Primary completion Jul 31, 2021
Drug: Fostemsavir 600 mg; Fostemsavir 200 mg · For: HIV Infections
Sites: Austin, Texas
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06182124 · 1,710 participants · Start Dec 20, 2023 · Primary completion May 12, 2026
Drug: Multivalent Pneumococcal Vaccine - Formulation 1; Multivalent Pneumococcal Vaccine - Formulation 2 and 4 more · For: Pneumococcal Disease
Sites: Doral, Florida; Miami Lakes, Florida; Stockbridge, Georgia · 17 sites in all
CureVacIndustry
NCT05252338 · 240 participants · Start Feb 7, 2022 · Primary completion Sep 27, 2022
Drug: CVSQIV · For: Influenza
Sites: Panama City, Panama · 3 sites in all
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT06746311 · 82 participants · Start Nov 22, 2022 · Primary completion May 13, 2024
Drug: HT-101; HT-101 and 1 more · For: Chronic Hepatitis b
Sites: Beijing, China; Guangzhou, China; Xuzhou, China · 7 sites in all
Suzhou HepaThera Biotech Co., Ltd.Industry
NCT06744686 · 56 participants · Start Jun 12, 2023 · Primary completion Mar 12, 2024
Drug: HT-102; HT-102 and 1 more · For: Chronic Hepatitis B
Sites: Fuzhou, China; Qingyuan, China; Luoyang, China · 7 sites in all
AstriVax TherapeuticsIndustry
NCT06989788 · 16 participants · Start May 6, 2025 · Primary completion Aug 10, 2026
Drug: AVX70371 · For: Chronic Hepatitis b
Sites: Ghent, Belgium
- A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial VaginosisPivotal-lookingCompleted
BioNTech SEIndustry
NCT06469164 · 102 participants · Start Jul 1, 2024 · Primary completion Jul 31, 2025
Drug: BNT331 · For: Bacterial Vaginosis
Sites: Birmingham, Alabama; Marrero, Louisiana; Metairie, Louisiana · 6 sites in all
Qpex Biopharma, Inc.Industry
NCT07104162 · 40 participants · Start Sep 16, 2025 · Primary completion Sep 4, 2026
Drug: Cefiderocol/Xeruborbactam · For: Bacterial Infections
Sites: Miami, Florida; Orlando, Florida
Sinovac Biotech Co., LtdIndustry
NCT07737106 · 50 participants · Start Aug 21, 2025 · Primary completion Sep 18, 2025
Drug: Influenza Vaccine (Split Virion), Inactivated (High Dose); Influenza Vaccine (Split Virion), Inactivated · For: Influenza
Sites: Bayan Nur, China
- Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in AdultsPivotal-lookingCompleted
SeqirusIndustry
NCT05875961 · 600 participants · Start Jun 15, 2023 · Primary completion Nov 15, 2024
Drug: Low dose A/H2N3c + standard dose MF59; Intermediate dose A/H2N3c + standard dose MF59 and 4 more · For: Influenza, Human; Infections; Respiratory Tract Infections and 2 more
Sites: Rockville, Maryland; Lincoln, Nebraska; Omaha, Nebraska · 7 sites in all
- [¹⁴C] Hydronidone Mass Balance StudyCompleted
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07471217 · 6 participants · Start Apr 17, 2026 · Primary completion May 6, 2026
Drug: [¹⁴C]Hydronidone · For: Chronic Hepatitis B-related Liver Fibrosis
Sites: Beijing, China
- Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in AdultsPivotal-lookingCompleted
Arcturus Therapeutics, Inc.Industry
NCT06602531 · 212 participants · Start Dec 10, 2024 · Primary completion Jun 13, 2025
Drug: ARCT-2304; Control vaccine younger adults and 1 more · For: Influenza, Human
Sites: La Mesa, California; San Bernardino, California; Longmont, Colorado · 4 sites in all
Rock BioMedical, Inc.Industry
NCT06878170 · 60 participants · Start Sep 30, 2024 · Primary completion Jan 26, 2026
Drug: RBM-001 · For: COVID-19
Sites: Miami, Florida
- A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06147063 · 243 participants · Start Nov 27, 2023 · Primary completion Apr 30, 2024
Drug: AZD9838; Licensed SARS-CoV-2 mRNA vaccine and 1 more · For: COVID-19; SARS-CoV-2 Infection
Sites: Long Beach, California; Rolling Hills Estates, California; Chicago, Illinois · 5 sites in all
- A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult VolunteersPivotal-lookingCompleted
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.Industry
NCT06082323 · 150 participants · Start Jun 13, 2024 · Primary completion Nov 25, 2025
Drug: LT-002-158/Placebo oral tablet(s) · For: Healthy Volunteer; Hidradenitis Suppurativa; Atopic Dermatitis
Sites: Shanghai, China
Aligos TherapeuticsIndustry
NCT06698549 · 12 participants · Start Feb 20, 2025 · Primary completion Jul 23, 2025
Drug: ALG-097558 · For: COVID 19
Sites: Miami, Florida; Orlando, Florida; Tampa, Florida
GlaxoSmithKlineGSK (GSK)
NCT04758962 · 10 participants · Start Feb 15, 2021 · Primary completion Jun 4, 2021
Drug: 1 µg CoV2 SAM (LNP) · For: Virus Diseases
Sites: Rochester, New York
SATO Pharmaceutical Co., Ltd.Industry
NCT05110638 · 19 participants · Start Sep 22, 2021 · Primary completion May 30, 2022
Drug: SKX-16 (Luliconazole 10% Solution) · For: Onychomycosis of Toenail
Sites: College Station, Texas
Aligos TherapeuticsIndustry
NCT07342881 · 12 participants · Start Mar 10, 2026 · Primary completion Jul 29, 2026
Drug: Pevifoscorvir Sodium (ALG-000184) · For: Chronic Hepatitis B Infection
Sites: Orlando, Florida; Tampa, Florida
Aligos TherapeuticsIndustry
NCT07342868 · 20 participants · Start Jan 30, 2026 · Primary completion Aug 19, 2026
Drug: Pevifoscorvir Sodium (ALG-000184) · For: Chronic Hepatitis B Infections
Sites: Orlando, Florida
- A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy PeoplePivotal-lookingCompleted
BioNTech SEIndustry
NCT06683352 · 1,353 participants · Start Nov 11, 2024 · Primary completion Jul 15, 2025
Drug: Investigational Influenza Vaccine; COVID-19 Vaccine and 2 more · For: Influenza,Human; COVID-19
Sites: Lake Forest, California; San Diego, California; Walnut Creek, California · 22 sites in all
Virion TherapeuticsIndustry
NCT06070051 · 35 participants · Start Sep 26, 2023 · Primary completion Mar 31, 2026
Drug: VRON-0200-AdC6; VRON-0200-AdC7 and 2 more · For: Chronic Hepatitis B
Sites: Hong Kong, Hong Kong; Auckland, New Zealand · 3 sites in all
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)Industry
NCT02687906 · 39 participants · Start Jul 2016 · Primary completion Jul 2026
Drug: Vabomere · For: Bacterial Infections
Sites: Little Rock, Arkansas; Los Angeles, California; Orange, California · 9 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.